[ FDA ENFORCEMENT INTELLIGENCE ]
Learn from the record. Every FDA recall is a quality signal.
Live drug, device & food recall data from the FDA (openFDA enforcement) — food spanning dietary supplements, cosmetics & animal food — mapped to the GxP quality domains SPEQ assesses, so you can see where control breaks down across every regulated industry.
1,000
Total recalls
217
Class I (most serious)
167
Drug
515
Device
318
Food / supplement / cosmetic
Last 12 months · latest report 2026-07-22 · source: openFDA enforcement
RECALLS BY CLASSIFICATION · MONTHLY
RECALL REASONS BY QUALITY DOMAIN
Domain mapping is a SPEQ interpretation of the FDA recall reason, not an official FDA classification.
3,493 matching recalls
| Date | Class | Firm | Reason | Quality domain |
|---|---|---|---|---|
| 2026-07-08 | Class II | CareFusion 213, LLCD-0644-2026 | Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel | Environmental Monitoring |
| 2026-07-08 | Class II | ACCORD HEALTHCARE, INC.D-0656-2026 | Subpotent Drug | Validation & Qualification |
| 2026-07-08 | Class II | McKessonD-0714-2026 | Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment. | Documentation & Change Control |
| 2026-07-08 | Class II | CareFusion 213, LLCD-0650-2026 | Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel | Environmental Monitoring |
| 2026-07-08 | Class II | Masimo CorporationZ-2671-2026 | Two devices recalled: 1) Electrocardiogram (ECG) electrode assembly ECG feature may incorrectly detect extreme bradycardia, tachycardia and trigger alarms on normal heart rate patients, which may distract clinicians away from management of true positive alarms, which could delay treatment; 2) Small and medium size blood pressure cuffs may contain rough edges, may result in skin irritation/redness. | Documentation & Change Control |
| 2026-07-08 | Class II | Blaine Labs IncD-0695-2026 | CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry | Validation & Qualification |
| 2026-07-08 | Class II | Blaine Labs IncD-0693-2026 | CGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminated | Environmental Monitoring |
| 2026-07-08 | Class II | Blaine Labs IncD-0699-2026 | CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated | Environmental Monitoring |
| 2026-07-08 | Class II | Siemens Medical Solutions USA, IncZ-2641-2026 | Potential for loss of movement capability after adjusting the detector lift height to its maximum or minimum limits. | — |
| 2026-07-08 | Class II | Blaine Labs IncD-0696-2026 | CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry | Validation & Qualification |
| 2026-07-08 | Class II | Lupin Pharmaceuticals Inc.D-0655-2026 | Presence of Foreign Substance | — |
| 2026-07-08 | Class II | CareFusion 213, LLCD-0651-2026 | Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel | Environmental Monitoring |
| 2026-07-08 | Class II | Boston Scientific CorporationZ-2634-2026 | Potential sterile breach of the pouches in which devices are packaged. | Environmental Monitoring |
| 2026-07-08 | Class II | Blaine Labs IncD-0694-2026 | CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry | Validation & Qualification |
| 2026-07-08 | Class III | SUN PHARMACEUTICAL INDUSTRIES INCD-0654-2026 | Failed Impurities/Degradation Specifications | Validation & Qualification |
| 2026-07-08 | Class I | Blaine Labs IncD-0692-2026 | Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus spp | Environmental Monitoring |
| 2026-07-08 | Class II | CareFusion 213, LLCD-0652-2026 | Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel | Environmental Monitoring |
| 2026-07-08 | Class II | Lupin Pharmaceuticals Inc.D-0723-2026 | CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing. | Validation & Qualification |
| 2026-07-08 | Class II | Blaine Labs IncD-0698-2026 | CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry | Validation & Qualification |
| 2026-07-08 | Class II | Asclemed USA Inc.D-0658-2026 | Lack of Assurance of Sterility | Environmental Monitoring |
| 2026-07-08 | Class II | Bard Access Systems, Inc.Z-2660-2026 | Due to lidocaine ampoules being manufactured under deficient manufacturing practices by manufacturer, lidocaine ampoules are currently being recalled by supplier. | Risk Management & CAPA |
| 2026-07-08 | Class II | Cipla USA, Inc.D-0661-2026 | cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). | Risk Management & CAPA |
| 2026-07-08 | Class II | Blaine Labs IncD-0697-2026 | CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry | Validation & Qualification |
| 2026-07-08 | Class II | CareFusion 213, LLCD-0643-2026 | Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel | Environmental Monitoring |
| 2026-07-08 | Class II | CareFusion 213, LLCD-0646-2026 | Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel | Environmental Monitoring |
Data: U.S. FDA openFDA enforcement API. Quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Recall details are as reported by the FDA.